Answers are grounded in this paper and cite their sources.
Compassionate use of dazukibart shows significant improvement in severe juvenile dermatomyositis, indicating its transformative potential.
In the current issue of JEADV, Fournier et al.1 describe dramatic and rapid recovery of children with severe juvenile dermatomyositis (JDM) treated with the interferon-beta (IFNβ) inhibitor dazukibart. A 15-year-old boy and 12-year-old girl (Patient 2) had over 5 years of persistent skin ulcerations and muscle weakness refractory to even third-line therapies, including systemic corticosteroids, methotrexate, intravenous immunoglobulin (IVIG), plasma exchange (PE) and Janus kinase inhibitors (JAKi). Patient 2 was unable to walk or sit up from bed and was receiving weekly PE and morphine. Under a compassionate access programme allowing for use of dazukibart in patients with serious or life-threatening disease, both patients received a single intravenous (IV) dose. As early as 4 weeks, both patients experienced dramatic muscle and skin improvement. Skin disease activity resolved and ulcerations healed. Patient 2 was walking within 4 weeks of the single dose and discontinued PE and morphine. Continued dazukibart monthly IV therapy resulted in continued improvement, including regression of calcinosis in one patient. No adverse side effects occurred. These children's responses are similar to the life-saving effect of dazukibart in another recent report of JDM compassionate access use.2 A 9-year-old girl with deep skin ulcers, interstitial lung disease and profound muscle weakness unable to lift her head off the bed, sit or walk despite 8 months of aggressive therapies developed extensive JDM-associated oesophageal, gastric and duodenal ulcers, resulting in a life-threatening duodenal perforation requiring intensive care unit (ICU) admission. Aggressive therapies including IVIG, subcutaneous methotrexate, mycophenolate mofetil and high dose cyclophosphamide (500 mg/m2 × 2) failed to achieve response. Emergency compassionate access use of a single IV dose of dazukibart resulted in dramatic improvement in skin, lung, muscle and gastrointestinal disease. By 4 weeks after a single dazukibart dose, skin ulcers had ceased to form and were healing, she was able to walk independently without assistive devices and returned to a full oral diet. Skin ulcers completely healed after a second dose, and at 14 months of continued therapy every 4–6 weeks, there had been no relapse of clinical skin, lung, muscle or gastrointestinal disease. No treatment-associated adverse events occurred. An additional publication describes compassionate access emergency use of dazukibart in an adult patient with MDA5 DM-associated rapidly progressive interstitial lung disease (RP-ILD), a condition with mortality approaching 80% in the first 3 months, whose skin and pulmonary function responded rapidly to dazukibart in an ICU setting.3 These compassionate access and emergency use dazukibart experiences in 3 children and 1 adult supplement the phase 2 placebo-controlled efficacy data demonstrating rapid and deep responses in a trial of 75 adult patients with dermatomyositis.4, 5 These compassionate use patients with life-threatening or severe disease who were ineligible for dazukibart clinical trials demonstrate the potential of dazukibart for transformative efficacy in patients with the most severe forms of DM, including those with RP-ILD, severe muscle disease resulting in disability, ulcerative skin disease and gastrointestinal involvement resulting in perforation. Notably, the pathophysiology of DM is mediated by IFNβ specifically.6, 7 Accordingly, as found by Fournier et al., the most targeted therapy towards IFNβ, dazukibart, was highly effective after multiple therapeutic failures. In personal experience (RAV), dazukibart has shown exceptional efficacy in treating severe and recalcitrant DM, with some patients entering long-term disease remission after treatment. Dr. Greenberg is an inventor of intellectual property related to dazukibart, assigned to and managed by Brigham and Women's Hospital, and licensed to Pfizer. Dr. Vleugels is an investigator for the Phase 3 dazukibart study. Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
No takes yet. Share an insight, caveat, or question.
Vleugels et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: